Navigation Links
gain in Biological Technology

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

... income (expenses): Foreign exchange (loss) gain (1,441) 1,441 f - ... income (expenses): Foreign exchange (loss) gain 140 (140) f - ... income (expenses): Foreign exchange (loss) gain (709) 709 g - ...

Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval

... and development expenses and a $10.2 million gain on the sale of CTI's remaining interest in a ... 3,820 - 3,944 - gain on sale of investment in joint ... (5,348) (41,146) Foreign exchange gain (loss) 54 76 95 ...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... 334.7 437.7 653.3 782.4 gain on sale of product rights - (9.1) ... 0.5 - 2.7 - gain on sale of long-lived assets (0.2) (0.4) (0.2) (0.4) gain on sale of non-current investments ...

CuraGen Reports Second Quarter 2009 Financial Results

... ----- ------ ------ ------ gain on sale of intangible asset - 36,397 ... (451) (334) (1,248) Realized (loss) gain on sale of available-for-sale investments, net (1) (165) 83 (169) gain on extinguishment of debt - 6,991 ...

ERT Reports Second Quarter 2009 Results

... of 2008. The Company reported a $0.5 million gain on the sale of the EDC operations, which is ... respectively. The Company reported a $0.5 million gain on the sale of the EDC operations, which is ... provided by operating activities: gain on sale of EDC operations ...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

... for the second quarter of 2009 is a $0.4 million gain resulting from a reduction between issuance and ... was a marginal decrease in the rate of weight gain in females at 1000 mg/kg, the highest dose ... 210 384 381 995 gain from valuation of common stock warrant ...

Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009

... remaining spending on accrued projects and a gain of approximately $10.4 million on the termination ... remaining spending on accrued projects and a gain of approximately $10.4 million on the ... the impact of tax synergies. (g) The gain of $10.4 million described in footnote (e) was ...

Vasogen Announces Second Quarter 2009 Results

... - - - (6,749) gain on sale of patents - ... - - - 125 gain on sale of patents - - ... foreign exchange gain (loss) 90 (33) 52 ...

Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results

... compared to $23,574,000, exclusive of the net gain of $40,170,000 from the settlement of our ... or $0.18 per diluted share, compared to a net gain for fiscal year 2008 of $37,107,000 or $1.18 per ... for fiscal year 2008 includes a one time net gain of $40,170,000 from the settlement of our ...

Biotech Shows Glimmer of an Upward Trend

... average posted its third straight monthly gain closing up 4 percent with the Nasdaq close behind ... Biotech Select Index posting a modest monthly gain of 0.4 percent. "There is just a glimmer of ... $970 million cash to acquire the company and gain access to compounds in development for the ...

Insmed Announces First Quarter 2009 Financial Results

... million improvement was primarily due to the gain on sale of our FOB assets to Merck which was ... (242) (354) gain on sale of asset, net 127,755 ... expense 1,439 133 gain on sale of asset, net (127,755) ...

Solutia Reports First Quarter 2009 Results

... comparability (detailed below) totaling a net gain of $1 million in 2009 and a net gain of $1,210 million in 2008. After adjusting for ... items and certain gains and losses totaling a net gain of $210 million. Despite continued demand ...

Shire begins the year with a strong performance

... shares from the disposal, recognizing a gain of $55 million in Q1 2009. A further gain of up to $8 million may be recognized in 2010 ... 2008 other income, net included a $9.4 million gain on the sale of a minority equity investment in ...

Medarex Announces 2009 First Quarter Financial Results

... of $103.3 million, or $0.81 per share, included a gain of $151.8 million, or $1.19 per share, from the ... affiliate 2,416 1,785 gain on sale of Genmab stock - ... are impairment loss on investments in partners, gain on sales of Genmab stock and equity in net loss ...

Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets

... diluted share after excluding the centralized ECG gain on sale). "On a consolidated basis, first ... $0.63 $0.76 (17.4%) gain on Sale, net of tax - $1.9 Net Income Excluding gain on Sale $40.3 $47.2 (14.6%) ...

ViroPharma Incorporated Reports First Quarter 2009 Financial Results

... our market capitalization at March 31, 2009, and gain on extinguishment of repurchased bonds. A ... of goodwill for $65.1 million, offset by the gain on our repurchase of our senior convertible notes ... (3,309) (3,127) gain on senior convertible note repurchase ...

Beckman Coulter Announces First Quarter 2009 Results

... and $0.7 million (including a net gain of $2.6 million gain on sale of building and land in ... expense 11.3 9.5 gain on sales of building and land - ...

Vasogen Announces First Quarter 2009 Results

... - - (6,749) gain on sale of patents 487 ... - - 125 gain on sale of patents (487) - ... Unrealized foreign exchange gain (38) 192 ...

Spherix Announces 2008 Financial Results

... in 2008 included a $2.0 million pre-tax gain upon the release of the escrow balance related to ... in 2007 included an $8.6 million pre-tax gain on the sale of InfoSpherix. The net loss for ... was partly offset by the $2 million pre-tax gain realized in November 2008 upon the receipt of the ...

ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes

... the accounting for the resulting net pre-tax gain in accordance with the company's adoption of FASB ... (Including Partial Cash Settlement). This gain will be reported in the financial statements for ... of 2009. ViroPharma anticipates that the taxable gain arising from the repurchase will qualify for ...

Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results

... in research and development expenses as well as a gain of $9.4 million on the sale of Zevalin to a 50/50 ... expense of $24.6 million in 2007 and a gain of $9.4 million on the sale of Zevalin to a 50/50 ... NDA in the first half of 2009 for pixantrone and gain approval in 2009, our ability to continue to ...

Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results

... (210) (226) (794) (547) gain on divestiture of product lines ... - 43,365 - gain on divestiture of product lines (5) ... 5) We exclude the impairment of goodwill and the gain on divestiture of product lines from this ...

OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

... primarily due to the impact of an extraordinary gain recognized in connection with the reverse ... Operating loss before extraordinary gain 4,955 2,223 8,632 8,536 Extraordinary gain - - 4,428 ...

Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008

... Other income (expenses): Foreign exchange gain (loss) (1,032) 1,032 h ... Other income (expenses): Foreign exchange gain (loss) 173 (173) h ... Other income (expenses): Foreign exchange gain (loss) 540 (540) h ...

ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results

... between the two years has led to a currency rate gain of EUR 0.02 million during 2008, compared to a ... a consequence, the financial result amounts to a gain of EUR 0.38 million in 2008 compared to a loss of ... 1 264 888 Exchange gain (loss) (700) ...

Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results

... of this transaction, the company recognized a gain of $69.6 million in the fourth quarter of 2008. ... 1,458 28,396 1,458 28,396 gain on sale of pulmonary assets ... (69,572) - (69,572) - gain on termination of collaborative ...

Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion

... relating to the New River acquisition). gain on sale of product rights For the year to ... 58.0 - sale securities gain on sale of available for sale security ... 2.8 - 10.3 1.3 gain on sale of product rights - (115.7) ...

Gentiva Reports Fourth Quarter and Fiscal 2008 Results

... unit in the third quarter. Excluding the net gain from CareCentrix and special charges, adjusted ... (113,247) (490,451) (444,042) gain on sale of business, net 61 ... (2,227) (856) gain on sale of business, net ...

Cephalon's New Product Launches Pace Record 2008 Sales

... (4,561) (28,493) (19,833) gain on extinguishment of debt - - - 5,319 gain on sale of investment - ... 7,450 (4) 425,000 (4) gain on sale of investment - (5) ...

Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals

... These restructuring charges include a net gain of $3.2 million related to the sale of ... held in escrow of $1.2 million and recorded a gain on sale in other non-operating income. The gain on sale of $26.2 million was recorded in ...

CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009

... ----- ------ ------ ------ gain on sale of intangible asset - ... (213) (995) (1,687) (5,167) gain on extinguishment of debt ... 6,991 8,442 Realized (loss) gain on sale of available-for- sale ...

The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance

... $0.2 million. Pretax income exclusive of currency gain totaled $1.3 million, an increase of 211% ... In FY2008, the Company recorded a currency gain of $1 million and recognized a tax benefit of $0.8 million. Pretax income exclusive of the currency gain totaled $3.2 million, which represented an ...

China-Biotics, Inc. Reports Second Quarter 2009 Financial Results

... was $4.5 million -- Excluding a $1.9 million gain related to the change in fair value of ... quarter of 2009 consisted of a $1.9 million book gain related to the change in the fair value of the ... was $4.5 million. Excluding the $1.9 million gain on the revaluation of the convertible notes, net ...

OncoGenex Reports Third Quarter Financial Results

... primarily due to the impact of an extraordinary gain on the reverse takeover of Sonus and a reversal ... example, statements of the Company's ability to gain FDA agreement on protocol design and time frames ... Operating income (loss) before extraordinary gain 149 (1,930) (3,676) ...

Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results

... 2009 quarter was primarily due to a non-cash gain of $2.9 million recorded in the fiscal 2008 ... 249 28 gain on sale of long-term investments 170 ... -- (633) Non-cash gain on decrease in fair value of warrants ...

Advanced Life Sciences Announces Third Quarter 2008 Financial Results

... 103,277 116,998 gain on sale of interest in Sarawak Medichem ... 310,296 350,268 gain on sale of interest in Sarawak Medichem ... 2,933,446 gain on sale of interest in Sarawak Medichem ...

InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008

... the third quarter of 2008 included a $5.4 million gain on derivative financial instruments, which is ... depreciation and amortization, and excludes gain (loss) on derivative financial instruments, and ... 5,578 Other income (expense): gain (loss) on derivatives 5,381 (675) ...

SuperGen Reports 2008 Third Quarter Financial Results

... on a cash basis when it is received. Excluding gain on sale of products, total costs and operating ... for the same prior year period. There was no gain on sale of products for the 2008 third ... $1.8 million for the same prior year period. The gain on sale of products for the 2007 third quarter ...

CuraGen Reports Third Quarter 2008 Financial Results

... 2008 and 2007 was primarily due to a gain of the sale of belinostat and a gain on the extinguishment of debt in the second ... 4,529 11,700 16,694 48,648 gain on sale of intangible asset - - ...

Shire's New Product Portfolio Delivers Strong Quarterly Performance

... acquisition related costs incurred by Jerini. gain on sale of product rights For the three months ... 7.5 - 7.5 1.3 gain on sale of product rights (4.0) (7.1) ... 120.5 - 120.5 1,896.0 gain on sale of product rights (4.0) (7.1) ...
Other Contents
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... Steven Chown has been awarded the Scientific Committee ... in Antarctic Research. , SCAR, an inter-disciplinary international ... international scientific research in the Antarctic region, and ... the Earth system. The organisation also provides scientific ... responsible for governing the region. , The medal ...
(Date:7/30/2014)... in cancer treatment has been shown to relieve ... for neural transmission between the peripheral and central ... Institute of Radiation Medicine, Chinese Academy of Medical ... into rat dorsal root ganglia (DRG) to provide ... radioactivity (0, 14.8, 29.6 MBq) were implanted separately ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2
(Date:7/31/2014)... The study, The Truth Behind Variation in ... care payments for four clinical areas—congestive heart failure, acute ... and knees). Using the definition of episodes of ... program, the study examines these clinical areas within the ... , “Our study reaffirms that, in most instances, the ...
(Date:7/30/2014)... Riverdale, NJ (PRWEB) July 31, 2014 ... in Macy’s ninth annual national “Shop For A Cause” ... For A Cause” is a unique one-day-only shopping event ... helped raise more than $44 million for charities across ... year’s event by purchasing shopping passes from Push to ...
(Date:7/30/2014)... Dayton, Ohio (PRWEB) July 31, 2014 ... welcome Douglas A. Fecher President and CEO, Wright-Patt Credit ... , Fecher, is a foremost financial CEO with an ... vice president of lending and later chief operating officer ... 2000, Fecher has led the Beavercreek-based Wright-Patt Credit Union ...
(Date:7/30/2014)... 31, 2014 WalkingSticksandCane.com has just ... The ladies will love the new European fashions and the ... These sticks and canes are from one from one of ... of the styles re unique and offer the consumer the ... Blackthorn Walking Sticks are some of the rarest and most ...
(Date:7/30/2014)... born with severe combined immunodeficiency (SCID) can be successfully ... to experts led by Memorial Sloan Kettering,s Richard J. ... transplant protocols. Their review will be published in the ... of Medicine . , SCID is a group of ... malfunction. When this breakdown occurs, babies no longer have ...
Breaking Medicine News(10 mins):Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 3Health News:European Walking Sticks from WalkingSticksandCane.com 2Health News:Transplantation shown to be highly effective in treating immune deficiency in children 2
Other TagsOther Tags